复杂性金黄色葡萄球菌血流感染持续性菌血症与死亡率的预后模型
研究评估了32例和124例两队列金黄色葡萄球菌菌血症患者初次就诊时血液蛋白与疾病严重程度结局的关联。鉴定出13种与死亡率和持续性菌血症相关的候选蛋白,IL-8与CCL2联合分类致死结局的敏感性为89%、特异性为77%(P<.0001)。基线IL-17A在持续性菌血症(P<.0001)、血管内感染(P=.026)和转移性组织感染(P=.012)患者中升高。
要点
- IL-8与CCL2联合预测死亡:敏感性89%、特异性77%(P<.0001)。
- 基线IL-17A在持续性菌血症患者中升高(P<.0001)。
- IL-17A在血管内感染(P=.026)和转移性组织感染(P=.012)中升高。
核心结论
- 所选生物标志物有潜力区分治疗失败和菌血症相关并发症风险最高的患者,为临床医生管理金黄色葡萄球菌菌血症提供工具。
- 这些生物标志物可识别最可能从临床试验中新疗法获益的患者。
研究设计与样本
- 评估两个金黄色葡萄球菌菌血症患者队列(n=32和n=124)初次就诊时一组血液蛋白与疾病严重程度结局的关联。
主要发现
- 鉴定出13种与死亡率和持续性菌血症相关的候选蛋白。
- 预后建模显示IL-8和CCL2是最强的个体死亡预测因子,两者联合分类致死结局的敏感性为89%、特异性为77%(P<.0001)。
- 基线IL-17A水平在持续性菌血症患者中升高(P<.0001),在血管内感染(P=.026)和转移性组织感染(P=.012)患者中也升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Staphylococcus aureus is a leading cause of bacteremia, yet there remains a significant knowledge gap in the identification of relevant biomarkers that predict clinical outcomes. Heterogeneity in the host response to invasive S. aureus infection suggests that specific biomarker signatures could be utilized to differentiate patients prone to severe disease, thereby facilitating earlier implementation of more aggressive therapies. METHODS: To further elucidate the inflammatory correlates of poor clinical outcomes in patients with S. aureus bacteremia, we evaluated the association between a panel of blood proteins at initial presentation of bacteremia and disease severity outcomes using 2 cohorts of patients with S. aureus bacteremia (n = 32 and n = 124). RESULTS: We identified 13 candidate proteins that were correlated with mortality and persistent bacteremia. Prognostic modeling identified interleukin (IL)-8 and CCL2 as the strongest individual predictors of mortality, with the combination of these biomarkers classifying fatal outcome with 89% sensitivity and 77% specificity (P < .0001). Baseline IL-17A levels were elevated in patients with persistent bacteremia (P < .0001), endovascular (P = .026) and metastatic tissue infections (P = .012). CONCLUSIONS: These results demonstrate the potential utility of selected biomarkers to distinguish patients with the highest risk for treatment failure and bacteremia-related complications, providing a valuable tool for clinicians in the management of S. aureus bacteremia. Additionally, these biomarkers could identify patients with the greatest potential to benefit from novel therapies in clinical trials.
引用
- Guimaraes AO, Cao Y, Hong K, et al. A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection. Clin Infect Dis. 2019. PMID: 30165412. doi:10.1093/cid/ciy739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。